Medicamentos para anemia
Estos son los medicamentos que KitCal reúne para anemia. La elección depende de la edad, la gravedad, el germen o la causa, y de las guías locales.
Código CIE-10 de referencia: D64.9 .
Dosis de cada medicamento
Dosis por kilo de peso tal como figuran en KitCal. En la app se ingresa el peso y se obtiene la dosis en mg y el volumen a administrar.
Ácido Fólico
| Presentación | Dosis | Frecuencia | Dosis máxima |
|---|---|---|---|
| Tableta Oral 0.5mg · 1mg | 0.25 - 1mg x día | — | — |
| Ampolla Endovenosa 1mg/2cc | 0.25 - 1mg x día | — | — |
0.25-1mg x día.
0.25 - 1mg x día
Eritropoyetina
| Presentación | Dosis | Frecuencia | Dosis máxima |
|---|---|---|---|
| Vial Endovenosa; subcutáneo 1000UI · 2000UI · 4000UI · 5000UI | Anemia del prematuro200 UI/kg x dosis | — | — |
| Insuficiencia renal50 - 100 UI/kg x dosis | — | — |
Conservar entre 4 - 8 °C
Hierro
| Presentación | Dosis | Frecuencia | Dosis máxima |
|---|---|---|---|
| Gotas Oral 25mg/1cc · 50mg/1cc | Dosis profiláctica1 - 2 mg/kg x día | cada 24 horas | — |
| Dosis terapéutica5 - 6 mg/kg x día | cada 12 - 24 horas | — | |
| Jarabe Oral 26.25mg/5cc · 50mg/5cc | Dosis profiláctica1 - 2 mg/kg x día | cada 24 horas | — |
| Dosis terapéutica5 - 6 mg/kg x día | cada 12 - 24 horas | — |
Mejor absorción cuando se administra 30 minutos antes de los alimentos
Fuentes
Ver las 26 referencias de estos medicamentos
- Wilson RD, O'Connor DL, Gratzer S, et al. Guideline No. 427: Folic Acid and Multivitamin Supplementation for Prevention of Folic Acid–Sensitive Congenital Anomalies. J Obstet Gynaecol Can. 2022;44(6):707-720.e1. doi:10.1016/j.jogc.2022.04.004
- Viswanathan M, Urrutia RP, Hudson KN, et al. Folic Acid Supplementation to Prevent Neural Tube Defects: A Limited Systematic Review Update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 230. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Aug. Appendix A Table 2, Current Guidelines for Folic Acid Supplementation. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK593620/table/appa.tab2/
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, et al. Scientific opinion on the tolerable upper intake level for folate. EFSA J. 2023;21(11):e08353. doi:10.2903/j.efsa.2023.8353
- Liu J, Chen B, Zhao X, et al. Best Evidence Summary of Folic Acid Supplementation for Prevention of Neural Tube Defects in Women of Childbearing Age. Nutrients. 2026;18(4):641. doi:10.3390 u18040641
- Zhang N, Zhou Z, Chi X, et al. Folic acid supplementation for stroke prevention: A systematic review and meta-analysis of 21 randomized clinical trials worldwide. Clin Nutr. 2024;43(7):1706-1716. doi:10.1016/j.clnu.2024.05.048
- Martínez-Maldonado MC, González-Leyva CP, Fuentes-Abolafio IJ, et al. Efficacy of folic acid supplementation in the prevention of cardiovascular disease - a systematic review and meta-analysis of randomized controlled trials. BMC Nutr. 2025;11:203. doi:10.1186/s40795-025-01178-z
- Muchengeti K, Maimela GR, Modjadji P, et al. Folic acid supplementation on inflammation and homocysteine in type 2 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Nutr Diabetes. 2024;14(1):22. doi:10.1038/s41387-024-00282-6
- Xie M, Chen L, Wang Y, et al. The effectiveness and safety of the active form of folate on biochemical parameters in women of childbearing age: A systematic review and meta-analysis. Medicine (Baltimore). 2025;104(50):e46564. doi:10.1097/MD.0000000000046564
- Chiavarini M, Naldini G, Fabiani R. Maternal Folate Intake and Risk of Childhood Brain and Spinal Cord Tumors: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2018;51(1-2):82-95. doi:10.1159/000490249
- Drugs.com. Retacrit Dosage [Internet]. Last updated Jun 22, 2025 [citado 2026 Feb 11]. Disponible en: https://www.drugs.com/dosage/retacrit.html
- Drugs.com. Epogen Dosage [Internet]. Last updated Nov 5, 2025 [citado 2026 Feb 11]. Disponible en: https://www.drugs.com/dosage/epogen.html
- Alanazi BK, Alruwaili TKR, Alruwaili BDM, Alruwaili WLQ, Alhazmi ZAH, Alruwaili HRH, et al. Efficacy and safety of erythropoietin and erythropoiesis-stimulating agents in the management of anemia in patients with chronic kidney disease: a systematic review. Int J Med Dev Ctries. 2025 Oct 21; Online First. doi: 10.24911/IJMDC.51-1758782697
- Bertazza Partigiani N, D'Uva A, Vigezzi S, Brazzale AR, Vidal E. Comparative efficacy of epoetin alfa vs. darbepoetin in children with chronic kidney disease: a systematic review, meta-analysis and cost-effectiveness analysis. Syst Rev. 2025;13(1):278. DOI: 10.1007/s40620-025-02303-8
- Rajput HS, Solanki S, Jain S, Verma S, Patel L, Ramani M, et al. Assessing the Effectiveness and Safety of Erythropoietin in Chronic Kidney Disease: An Observational Study. Res J Pharm Technol. 2025;18(12):5807-3. DOI: 10.52711/0974-360X.2025.00837
- Zayed B, Mohamed A, Elnaggar M, et al. A systematic review and meta-analysis of factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents. Syst Rev. 2024;13:278. DOI: 10.1186/s13643-024-02689-x
- Hakim SM, Ahmad AHM, Amer AM. Effect of Preoperative Recombinant Human Erythropoietin on the Need for Blood Transfusion and Surgical Outcomes in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis with Trial Sequential Analysis. J Cardiothorac Vasc Anesth. 2024;38(10):2402-11. DOI: 10.1053/j.jvca.2024.06.017
- Fawzy A, Pels A, et al. Recombinant erythropoietin for the treatment of iron deficiency anemia in pregnancy: A systematic review. Int J Gynaecol Obstet. 2025 Jan;168(1):35-42. DOI: 10.1002/ijgo.15811
- Insiripong S, Yingsitsiri W, Boondumrongsagoon J, Noiwatanakul J. High Dose Erythropoietin for the Unexplained Anemia in the Elderly. Maharat Nakhon Ratchasima Hosp J. 2024;38(1):11-6
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease. Kidney Int. 2026;109(1):1-156.
- Benson AE, Grotzke MK, Al-Samkari H, et al. Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations. Lancet Haematol. 2025;12(5):e376-e388. doi:10.1016/S2352-3026(25)00038-9.
- Babitt JL, Berns JS, Bozkurt B, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1):44-56.
- Xue Q, Wang L, Zhang Y, et al. Efficacy and safety of intravenous iron supplementation for perioperative iron deficiency anemia: a systematic review and network meta-analysis of randomized controlled trials. J Clin Anesth. 2025;108:112062. doi:10.1016/j.jclinane.2025.112062.
- Mubarak M, Fatima A, Riaz S, et al. Efficacy and Safety of Intravenous Versus Oral Iron in Treating Maternal Anaemia During Pregnancy: A Systematic Review and Meta-Analysis. Cureus. 2025;17(9):e92775. doi:10.7759/cureus.92775.
- DrugDocs. Ferric Carboxymaltose (Injectafer) - Summary of Evidence from Systematic Reviews. DrugDocs.com
- Anker SD, Khan MS, Butler J, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. 2025;31(8):2640-2646. doi:10.1038/s41591-025-03671-1.
- DrugDocs. Ferric Carboxymaltose (Injectafer) - Heart Failure Evidence. DrugDocs.com;
Preguntas frecuentes
¿Qué medicamentos se usan para anemia?
KitCal reúne 3 medicamentos para anemia: Ácido Fólico, Eritropoyetina y Hierro. La elección depende de la edad, la gravedad y las guías locales.
¿Cuál es la dosis de ácido fólico para anemia?
Ácido Fólico (Tableta): 0.25 - 1mg x día. Con el peso del paciente, KitCal calcula la dosis y el volumen exactos.
¿Cómo se calcula la dosis por peso?
Se multiplica la dosis por kilo por el peso del paciente y se divide según la frecuencia indicada, sin superar la dosis máxima. Después se convierte a volumen según la concentración de la presentación. La app de KitCal hace este cálculo automáticamente.
¿Cuál es el código CIE-10 de anemia?
El código CIE-10 de referencia es D64.9.
Otras patologías
Contenido referencial para profesionales de la salud. No reemplaza el juicio clínico ni la evaluación del paciente.